Vertex Pharmaceuticals Incorporated (VRTX) Income Statement

The 12.5% growth in 2026Q2 marks an acceleration from the 7.8% in 2026Q1 and the 3.1% in 2025Q1, indicating that the diversification into pain and gene editing is gaining traction. While the CF franchise remains the core, the incremental revenue from non-CF products appears to be contributing to a higher growth trajectory. Investors should monitor whether this pace is sustainable as the acute pain market becomes more competitive.

The slight decline from 86.8% in 2026Q1 to 85.3% in 2026Q2 may reflect the higher cost structure of cell and gene therapies, but the absolute level remains robust, indicating strong pricing power. As the product mix shifts toward Casgevy and other biologics, gross margin could face structural pressure, but the current data suggests management is managing costs effectively. The high gross margin provides a cushion for continued R&D investment.

The operating margin recovery from the depressed 22.7% in 2025Q1 to 37.4% in 2026Q2 demonstrates significant operating leverage, with SG&A growing only modestly relative to revenue. R&D expenses have remained relatively flat around $1B per quarter, indicating that the company is scaling revenue without proportional increases in overhead. This suggests that the commercial infrastructure is efficient and that incremental revenue is highly profitable.

The consistent R&D spend of approximately $1B per quarter indicates a deliberate strategy to build a multi-franchise portfolio, with programs in pain, sickle cell, and endocrine diseases. While this high fixed cost base pressures near-term margins, it is essential for long-term growth and reducing reliance on the CF franchise. The recent guidance raise suggests that management sees a favorable return on this investment.